Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00022581

Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma +1 more

COMPLETED PHASE2

Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

NCT00151281

Non-Hodgkin's Lymphoma

COMPLETED PHASE2

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

NCT01301391

Malignant Thymoma

TERMINATED PHASE2

Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

NCT01011439

Thymic Carcinoma

TERMINATED PHASE2

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00015912

Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objectives of this study are to evaluate the effectivity and the safety of thalidomide in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation. It is a phase II prospective single arm study with a target sample size of 16 patients. Thalidomide is given orally at an initial dose of 100 mg for a maximum duration of 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

MALT Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thalidomide, Pharmion

200 mg p.o. daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with histologically confirmed MALT lymphoma with measurable disease (Stage I-IV)
* With first or greater relapse after HP-eradication, radiation or chemotherapy
* Age \> 18
* Must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
* ECOG status \_\< 2
* Must be capable of understanding the purpose of the study and have given written informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No